A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

The trial found that antibody levels were higher for COVID and all but one flu strain in those who got the combo.

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

Moderna’s new combination vaccine for seasonal influenza and COVID-19 has outperformed current standard vaccines in a large phase 3 clinical trial, showing stronger immune responses to both viruses in ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Moderna previously reported a summary of ... asking the company to run a new clinical trial of its protein-based COVID-19 vaccine after the agency grants full approval, sowing uncertainty about ...